JP6728055B2 - Ｉｌ−１５部分とポリマーとのコンジュゲート - Google Patents
Ｉｌ−１５部分とポリマーとのコンジュゲート Download PDFInfo
- Publication number
- JP6728055B2 JP6728055B2 JP2016559891A JP2016559891A JP6728055B2 JP 6728055 B2 JP6728055 B2 JP 6728055B2 JP 2016559891 A JP2016559891 A JP 2016559891A JP 2016559891 A JP2016559891 A JP 2016559891A JP 6728055 B2 JP6728055 B2 JP 6728055B2
- Authority
- JP
- Japan
- Prior art keywords
- moiety
- conjugate
- water
- polymer
- daltons
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461974914P | 2014-04-03 | 2014-04-03 | |
| US61/974,914 | 2014-04-03 | ||
| PCT/US2015/023871 WO2015153753A2 (en) | 2014-04-03 | 2015-04-01 | Conjugates of an il-15 moiety and a polymer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020074680A Division JP2020114875A (ja) | 2014-04-03 | 2020-04-20 | Ｉｌ−１５部分とポリマーとのコンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017511322A JP2017511322A (ja) | 2017-04-20 |
| JP2017511322A5 JP2017511322A5 (https=) | 2018-04-12 |
| JP6728055B2 true JP6728055B2 (ja) | 2020-07-22 |
Family
ID=54241432
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016559891A Active JP6728055B2 (ja) | 2014-04-03 | 2015-04-01 | Ｉｌ−１５部分とポリマーとのコンジュゲート |
| JP2020074680A Withdrawn JP2020114875A (ja) | 2014-04-03 | 2020-04-20 | Ｉｌ−１５部分とポリマーとのコンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020074680A Withdrawn JP2020114875A (ja) | 2014-04-03 | 2020-04-20 | Ｉｌ−１５部分とポリマーとのコンジュゲート |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20170035898A1 (https=) |
| EP (2) | EP3919071A1 (https=) |
| JP (2) | JP6728055B2 (https=) |
| KR (1) | KR102432169B1 (https=) |
| CN (1) | CN106456716A (https=) |
| AU (3) | AU2015240806B2 (https=) |
| CA (1) | CA2942571C (https=) |
| ES (1) | ES2876433T3 (https=) |
| IL (1) | IL248169A0 (https=) |
| MA (1) | MA39711A (https=) |
| MX (2) | MX388865B (https=) |
| WO (1) | WO2015153753A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2986306A4 (en) | 2013-04-18 | 2016-12-07 | Armo Biosciences Inc | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING |
| ES2688206T3 (es) | 2013-06-17 | 2018-10-31 | Armo Biosciences, Inc. | Procedimiento de evaluación de la identidad y la estabilidad de proteínas |
| CN105658232A (zh) | 2013-08-30 | 2016-06-08 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素-10治疗疾病和病症的方法 |
| EP3068425B1 (en) | 2013-11-11 | 2021-01-27 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| WO2015187295A2 (en) | 2014-06-02 | 2015-12-10 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
| WO2016060996A2 (en) | 2014-10-14 | 2016-04-21 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
| AU2015336101A1 (en) | 2014-10-22 | 2017-04-20 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
| CA2986755A1 (en) | 2015-05-28 | 2016-12-01 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
| US10398761B2 (en) | 2015-08-25 | 2019-09-03 | Armo Biosciences, Inc. | Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers |
| AU2016335860B2 (en) | 2015-10-08 | 2023-08-10 | Nektar Therapeutics | Combination of an IL-2Rbeta-selective agonist and a long-acting IL-15 agonist |
| US20180360977A1 (en) * | 2015-12-21 | 2018-12-20 | Armo Biosciences, Inc. | Interleukin-15 Compositions and Uses Thereof |
| JP7185530B2 (ja) | 2016-06-13 | 2022-12-07 | トルク セラピューティクス， インコーポレイテッド | 免疫細胞機能を促進するための方法および組成物 |
| US12036283B2 (en) * | 2017-05-15 | 2024-07-16 | Nektar Therapeutics | Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods |
| JP7285828B2 (ja) | 2017-09-05 | 2023-06-02 | トルク セラピューティクス， インコーポレイテッド | 治療用タンパク質組成物ならびにその作製および使用方法 |
| CA3091857A1 (en) * | 2018-02-26 | 2019-08-29 | Synthorx, Inc. | Il-15 conjugates and uses thereof |
| WO2020097556A1 (en) * | 2018-11-09 | 2020-05-14 | Nektar Therapeutics | Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent |
| KR20220004134A (ko) * | 2019-04-26 | 2022-01-11 | 프로린크스 엘엘시 | 서방형 사이토카인 컨쥬게이트 |
| WO2020247388A2 (en) | 2019-06-03 | 2020-12-10 | Medikine, Inc. | Il-2alpha receptor subunit binding compounds |
| CN114555632A (zh) * | 2019-08-23 | 2022-05-27 | 新索思股份有限公司 | Il-15缀合物及其用途 |
| AU2022249281B2 (en) * | 2021-03-29 | 2025-08-14 | Aj Sciences (Yixing) Co., Ltd | Protein-macromolecule conjugates and methods of use thereof |
| CN117597355A (zh) | 2021-06-23 | 2024-02-23 | 赛腾制药 | 白细胞介素15变体 |
| EP4370536A4 (en) * | 2021-07-12 | 2026-04-22 | Nektar Therapeutics | MODIFIED POLYMER FORMS OF INTERFERON-GAMMA AND METHODS OF USE |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2025101551A1 (en) * | 2023-11-06 | 2025-05-15 | Regents Of The University Of Minnesota | Prostate-specific membrane antigen (psma)-binding peptides and method of use |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| EP0728210B1 (en) * | 1993-11-12 | 2005-04-13 | Gilead Sciences, Inc. | Thrombin mutants |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| PT772624E (pt) | 1994-04-06 | 2001-03-30 | Immunex Corp | Interleucina-15 |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US7008624B1 (en) * | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
| US5795966A (en) * | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| DK1411075T3 (da) | 1998-03-12 | 2008-10-27 | Nektar Therapeutics Al Corp | Fremgangsmåde til fremstilling af polymerkonjugater |
| WO2001062827A2 (en) | 2000-02-22 | 2001-08-30 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| WO2004060965A2 (en) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| EP1581582B2 (en) | 2003-01-06 | 2017-06-07 | Nektar Therapeutics | Thiol-selective water-soluble polmer derivatives |
| US7276478B2 (en) * | 2003-09-25 | 2007-10-02 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
| US20060057680A1 (en) * | 2004-08-11 | 2006-03-16 | Zheng Xin X | Mutant interleukin-15 polypeptides |
| JP2008515896A (ja) | 2004-10-05 | 2008-05-15 | オクスナー クリニック ファウンデーション | Ｉｌ−１５によるｂ細胞増殖の増強 |
| US20060257361A1 (en) * | 2005-04-12 | 2006-11-16 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Novel form of interleukin-15, Fc-IL-15, and methods of use |
| BRPI0611872B8 (pt) | 2005-06-16 | 2021-05-25 | Nektar Therapeutics | reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica |
| KR101508621B1 (ko) | 2007-02-28 | 2015-04-07 | 세리나 쎄라퓨틱스, 인코포레이티드 | 활성화된 폴리옥사졸린 및 이를 포함하는 조성물 |
| CA2740904C (en) * | 2008-10-21 | 2019-01-15 | Baxter International Inc. | Methods for determining active ingredients in pro-drug peg protein conjugates with releasable peg reagents (in vitro de-pegylation) |
| DK2598172T3 (da) * | 2010-07-30 | 2019-07-01 | Baxalta GmbH | Nukleofile katalysatorer til oximforbindelse |
| ES2866674T3 (es) * | 2010-11-12 | 2021-10-19 | Nektar Therapeutics | Conjugados de una fracción de IL-2 y un polímero |
| CN102145178B (zh) * | 2011-04-15 | 2012-09-26 | 北京凯因科技股份有限公司 | Peg化白介素15 |
| WO2013020079A2 (en) * | 2011-08-04 | 2013-02-07 | Nektar Therapeutics | Conjugates of an il-11 moiety and a polymer |
-
2015
- 2015-03-31 MA MA039711A patent/MA39711A/fr unknown
- 2015-04-01 WO PCT/US2015/023871 patent/WO2015153753A2/en not_active Ceased
- 2015-04-01 AU AU2015240806A patent/AU2015240806B2/en active Active
- 2015-04-01 EP EP21169371.8A patent/EP3919071A1/en active Pending
- 2015-04-01 CA CA2942571A patent/CA2942571C/en active Active
- 2015-04-01 CN CN201580017361.XA patent/CN106456716A/zh active Pending
- 2015-04-01 MX MX2016012908A patent/MX388865B/es unknown
- 2015-04-01 KR KR1020167027127A patent/KR102432169B1/ko active Active
- 2015-04-01 ES ES15773976T patent/ES2876433T3/es active Active
- 2015-04-01 EP EP15773976.4A patent/EP3139947B8/en active Active
- 2015-04-01 US US15/301,681 patent/US20170035898A1/en not_active Abandoned
- 2015-04-01 JP JP2016559891A patent/JP6728055B2/ja active Active
-
2016
- 2016-09-30 MX MX2021015492A patent/MX2021015492A/es unknown
- 2016-10-02 IL IL248169A patent/IL248169A0/en active IP Right Grant
-
2019
- 2019-12-16 AU AU2019283778A patent/AU2019283778A1/en not_active Abandoned
-
2020
- 2020-04-20 JP JP2020074680A patent/JP2020114875A/ja not_active Withdrawn
-
2021
- 2021-10-28 AU AU2021258008A patent/AU2021258008A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20170035898A1 (en) | 2017-02-09 |
| AU2019283778A1 (en) | 2020-01-16 |
| EP3139947A4 (en) | 2018-01-17 |
| EP3139947B8 (en) | 2021-06-30 |
| EP3919071A1 (en) | 2021-12-08 |
| WO2015153753A3 (en) | 2015-11-26 |
| MA39711A (fr) | 2015-10-08 |
| JP2017511322A (ja) | 2017-04-20 |
| EP3139947A2 (en) | 2017-03-15 |
| WO2015153753A2 (en) | 2015-10-08 |
| IL248169A0 (en) | 2016-11-30 |
| MX2021015492A (es) | 2022-02-22 |
| AU2021258008A1 (en) | 2021-11-25 |
| KR102432169B1 (ko) | 2022-08-11 |
| AU2015240806A1 (en) | 2016-10-13 |
| EP3139947B1 (en) | 2021-05-26 |
| MX2016012908A (es) | 2017-01-11 |
| CA2942571C (en) | 2023-09-19 |
| KR20170005793A (ko) | 2017-01-16 |
| MX388865B (es) | 2025-03-20 |
| CN106456716A (zh) | 2017-02-22 |
| AU2015240806B2 (en) | 2019-09-19 |
| ES2876433T3 (es) | 2021-11-12 |
| CA2942571A1 (en) | 2015-10-08 |
| JP2020114875A (ja) | 2020-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6728055B2 (ja) | Ｉｌ−１５部分とポリマーとのコンジュゲート | |
| JP7850124B2 (ja) | Ｉｌ－２部分とポリマーとのコンジュゲート | |
| JP2022163194A (ja) | Ｉｌ－７部分とポリマーとのコンジュゲート | |
| AU2018270926B2 (en) | Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods | |
| BRPI0614257A2 (pt) | conjugados de uma porção de g-csf e um polìmero | |
| JP6626045B2 (ja) | コリンエステラーゼ部分とポリマーとのコンジュゲート | |
| WO2013020079A2 (en) | Conjugates of an il-11 moiety and a polymer | |
| HK1235666B (en) | Conjugates of il-15 and branched polyethylene glycol | |
| HK1235666A1 (en) | Conjugates of il-15 and branched polyethylene glycol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161012 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180301 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180301 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190128 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190424 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190627 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190725 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20191220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200420 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200611 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200619 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200701 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6728055 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |